tiprankstipranks
Company Announcements

Universe Pharmaceuticals Faces Nasdaq Delisting Risk Due to Delayed Annual Report

Story Highlights
Universe Pharmaceuticals Faces Nasdaq Delisting Risk Due to Delayed Annual Report

Universe Pharmaceuticals ( (UPC) ) just unveiled an announcement.

On February 19, 2025, Universe Pharmaceuticals INC announced it received a staff determination notice from Nasdaq due to a delay in filing its Annual Report for the fiscal year ended September 30, 2024. This delay is an additional basis for potential delisting from Nasdaq. The company is seeking to stay the suspension of its securities while working to complete the filing. This situation highlights the company’s current compliance challenges with Nasdaq’s listing requirements, which could impact its market positioning and investor relations.

More about Universe Pharmaceuticals

Universe Pharmaceuticals INC, based in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor specializing in traditional Chinese medicine derivatives aimed at improving the well-being of the elderly. The company also distributes biomedical drugs, medical instruments, and dietary supplements across 30 provinces in China.

YTD Price Performance: -75.27%

Average Trading Volume: 13,694,474

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.38M

See more data about UPC stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App